Simpler Grants.gov #FOR-FD-26-004

FDA Solicitation for Innovative Research in Ultra-Rare Cancer Therapeutics

The Food and Drug Administration (FDA), under the Department of Health and Human Services, is inviting proposals for innovative research to support therapeutic development in ultra-rare pediatric and adult cancers. - Government Buyer: - Food and Drug Administration (FDA), Department of Health and Human Services - OEMs and Vendors: - No specific OEMs or vendors are named in this solicitation - Products/Services Requested: - Research and development services focused on: - Infrastructure for data coordination networks - Validation of clinical endpoints for ultra-rare cancers - Collaborative real-world data generation - Innovative clinical development for discontinued drugs - Integration of telemedicine in clinical trials - Nanoparticle-based delivery of therapeutic nucleic acids - Comprehensive characterization of plasma-membrane protein expression in ultra-rare cancers - Unique or Notable Requirements: - Emphasis on ultra-rare cancers, including molecularly-defined subsets of common cancers - Encourages collaborative, multi-institutional, and innovative approaches - Focus on preserving drug availability and improving clinical trial design - Open to a broad range of applicants: educational institutions, government entities, nonprofits, and businesses - Funding provided via cooperative agreement; no cost sharing or matching required

Description

This program aims to support new approaches to facilitate therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers. Areas of interest include developing infrastructure for data coordination, validating early clinical endpoints, supporting real-world data use, identifying new clinical development opportunities for drugs, preserving availability of discontinued drugs, incorporating telemedicine in trials, nanoparticle-based delivery for therapeutic nucleic acids, and characterizing plasma-membrane protein expression in ultra-rare cancers. Eligible applicants include educational institutions, government entities, nonprofits, and businesses. The funding instrument is a cooperative agreement with no cost sharing required.

View original listing